Trial Profile

A potential registrational study of TPST-2003 in relapsed/refractory multiple myeloma in the U.S.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 18 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 May 2026 According to Tempest Therapeutics media release, the observed safety profile together with the consistency of responses observed in the REDEEM-1 trial continue to support Tempest's plan to pursue its objective of meeting with the FDA to discuss initiating a U.S. registrational study later this year.
22 Apr 2026 According to Tempest Therapeutics media release, the tech transfer is on track to support initiation of potentially registrational study in Q4 2026.
11 Mar 2026 According to Tempest Therapeutics media release, the company has partnered with Cincinnati Children's Applied Gene and Cell Therapy Center (AGCTC) as the lead contract development and manufacturing partner to conduct the formal technology transfer of TPST-2003 in preparation of this planned study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com